Antimalarial effect of iron chelators

Advances in Experimental Medicine and Biology

Volumn 509, Issue , 2003, Pages 251-272

  Gordeuk, Victor R ^a   Loyevsky, Mark ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2' BIPYRIDINE; 4 AMINOBUTYRIC ACID; 8 QUINOLINOL; AMINOTHIOL; DAPHNETIN; DEFERIPRONE; DEFEROXAMINE; DEFERRIFERRITHIOCIN; FANSIDAR; IRON CHELATING AGENT; N,N' BIS(2 HYDROXYBENZYL)ETHYLENEDIAMINE N,N' DIACETIC ACID; PYRIDOXAL ISONICOTINOYLHYDRAZONE; QUININE; RAZOXANE; SIDEROPHORE; VIBRIOBACTIN; ANTIMALARIAL AGENT; IRON; PYRIDONE DERIVATIVE;

ANTIMALARIAL ACTIVITY; BRAIN MALARIA; CLINICAL TRIAL; COMA; DNA SYNTHESIS; DRUG EFFECT; ELECTRON TRANSPORT; ERYTHROCYTE; HUMAN; IN VITRO STUDY; MALARIA; MITOCHONDRION; MORTALITY; NONHUMAN; PARASITE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; TROPHOZOITE; ANIMAL; CHILD; DRUG COMBINATION; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MALARIA FALCIPARUM; METABOLISM; PARASITOLOGY;

CINCHONA PUBESCENS; PLASMODIUM FALCIPARUM;

ANIMALS; ANTIMALARIALS; CHILD; DEFEROXAMINE; DRUG THERAPY, COMBINATION; HUMANS; IRON; IRON CHELATING AGENTS; MALARIA; MALARIA, CEREBRAL; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PYRIDONES;

EID: 0347383904     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (80)

1. Chakrabarti D, Schuster SM, Chakrabarti R. Cloning and characterization of subunit genes of ribonucleotide reductase, a cell-cycle-regulated enzyme, from Plasmodium falciparum. Proc Natl Acad Sci USA 1993 Dec 15:90(24):12020-4
2. Rubin H, Salem HS, Li LS, Yang FD, Mama S, Wang ZM, Fisher A, Hamann CS, Cooperman BS. Cloning sequence determination, and regulation of the ribonucleotide reductase subunits from Plasmodium falciparum: a target for antimalarial therapy. Proc Natl Acad Sci USA 1993; 90: 9280-9284.
3. Krungkrai J, Cerami A, Henderson GB. Purification and characterization of dihydroorotate dehydrogenase from the rodent malaria parasite Plasmodium berghei. Biochemistry 1991; 30: 1934-9.
4. Bonday ZQ, Taketani S, Gupta PD, Padmanaban G. Heme biosynthesis by the malarial parasite. Import of delta-aminolevulinate dehydrase from the host red cell. J Biol Chem 1997; 272: 21839-21846.
5. Krungkrai J, Krungkrai SR, Suraveratum N, Prapunwattana P. Mitochondrial ubiquinol-cytochrome c reductase and cytochrome c oxidase: chemotherapeutic targets in malarial parasites. Biochem Mol Biol Int 1997; 42: 1007-14.
6. Petmitr S, Krungkrai J. Mitochondrial cytochrome b gene in two developmental stages of human malarial parasite Plasmodium falciparum. Southeast Asian J Trop Med Public Health 1995; Dec:26(4):600-5
7. Reichard P, Ehrenberg, A. Ribonucleotide reductase - a radical enzyme. Science 1983; 221: 514-519.
8. Cavanaugh PF, Porter CW, Tukalo D, Frankfurt DS, Pavelic ZP, Bergeron RJ. Characterization of L1210 cell growth inhibition by the bacterial iron chelators parabactin and compound II. Cancer Res 1985; 45: 4754-4759.
9. Nyholm S, Mann GJ, Johansson AG, Bergeron RJ, Graslund A, Thelander L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem 1993; 268: 26200-26205.
10. Moormann AM, Hossler PA, Meshnick SR. Deferoxamine effects on Plasmodium falciparum gene expression. Mol Biochem Parasitol 1999; 98: 279-283.
11. Fuchs O, Ponka P. The role of iron supply in the regulation of 5-aminolevulinate synthase mRNA levels in murine erythroleukemia cells. Neoplasma 1996; 43: 31-36.
12. Surolia N, Padmanaban G. De novo biosynthesis of heme offers a new chemotherapeutic target in the human malarial parasite. Biochem Biophys Res Commun 1992; 187: 744-750.
13. Aikawa M, Wernsdorfer WH, McGregor I, Livingstone C, Edinburgh. Fine structure of malaria parasites in the various stages of development, In: Principles and Practice of Malariology 1988; 97-130.
14. Pouvelle B, Spiegel R, Hsiao L, Howard RJ, Morris RL, Thomas AP, Taraschi TF. Direct access to serum macromolecules by intraerythrocytic malaria parasites. Nature 1991; 353: 73-75.
15. Loyevsky M, Lytton SD, Mester B, Libman J, Shanzer A, Cabantchik ZI. The antimalarial action of Desferal involves a direct access route to erythrocytic (Plasmodium falciparum) parasites. J Clin Invest 1993; 91: 218-224.
16. Slater AF, Cerami A. Inhibition by chloroquine of a novel heme polymerase enzyme activity in malaria trophozoites. Nature 1992; 355: 167-169.
17. Pollack S, Flemming J. P. falciparum takes up iron from transferrin. Brit J Haematol 1984; 58: 289-293.
18. Pollack S, Schnelle V. Inability to detect transferrin receptors on P. falciparum parasitized red cells. Brit J Haematol 1988; 68: 125-129.
19. Sanchez-Lopez R, Halder K. A transferrin-independent iron uptake activity in Plasmodium falciparum-infected and uninfected erythrocytes. Mol Biochem Pharmacol 1992; 55: 9-20.
20. Hershko C, Peto TE. Deferoxamine inhibition of malaria is independent of host iron status. J Exp Med 1998; 168: 375-387.
21. Peto TE, Thompson JL. A reappraisal of the effects of iron and desferrioxamine on the growth of Plasmodium falciparum 'in vitro': the unimportance of serum iron. Brit J Haematol 1986; 63: 273-280.
22. Cazzola M, Arioso P, Barosi G, Bergamaschi G, Dezza L, Ascari E. Ferritin in the red cells of normal subjects and patients with iron deficiency and iron overload. Brit. J. Haematol 1983; 53: 659-665.
23. Gabay, T, Ginsburg, H. Haemoglobin denaturation and iron release in acidified red blood cell lysate - a possible source of iron for intraerythrocytic malaria parasites. Exp. Parasitol 1993; 77: 261-272.
24. Loyevsky M, John C, Dickens B, Hu V, Gordeuk VR. Chelation of iron within the erythrocytic Plasmodium falciparum parasite by iron chelators. Mol Biochem Parasitol 1999; 101:43-59.
25. Scott MD, Ranz A, Kuypers FA, Lubin BH, Meshnick SR. Parasite uptake of desferrioxamine: a prerequisite for antimalarial activity. Brit J Haematol 1990; 75: 598-603.
26. Raventos-Suarez C, Pollack S, Nagel RL. Plasmodium falciparum: inhibition of in vitro growth by desferrioxamine. Am J Trop Med Hyg 1982; 31: 919-922.
27. Heppner DG, Hallaway PE, Kontoghiorghes GJ, Eaton JW. Antimalarial properties of orally active iron chelators. Blood 1998; 72: 358-361.
28. Fritsch G, Sawatzki G, Treumer J, Jung A, Spira DT. Plasmodium falciparum: inhibition in vitro with lactoferrin, desferrithiocin and desferricrocin. Exp Parasitol 1987; 63:1-9.
29. Clarke CJ, Eaton JM. Hydrophobic iron chelators as new antimalarial drugs. Clin Res 1990; 38: 300A.
30. Loyevsky M, John C, Zaloujnyi I, Gordeuk V. Aminothiol multidentate chelators as antimalarials. Biochem Pharmacol 1997; 54: 451-458.
31. Scheibel LW, Adler A. Anti-malarial activity of selected aromatic chelators. Mol Pharmacol 1980; 18: 320-325.
32. Scheibel LW, Stanton GG. Anti-malarial activity of selected aromatic chelators IV. Cation uptake of Plasmodium falciparum in the presence of oxines and siderochromes. Mol Pharmacol 1986; 30: 364-369.
33. Hershko C, Theanacho EN, Spira DT, Peter HH, Dobbin P, Hider RC. The effect of N-alkyl modification on the antimalarial activity of 3-hydroxyppyridin-4-one oral iron chelators. Blood 1991; 77: 637-643.
34. Shanzer A, Libman J, Lytton SD, Glickstein H, Cabantchik ZI. Reversed siderophores act as anti-malarial agents. Proc Natl Acad Sci USA 1991; 88: 6585-6589.
35. Lytton SD, Loyevsky M, Mester B, Libman J, Landau I, Shanzer A, Cabantchik ZI. In vivo antimalarial action of a lipophilic iron (III) chelator: suppression of Plasmodium vinckei infection by reversed siderophore. Am J Hematol 1993; 43: 217-220.
36. Cabantchik ZI, Glickstein H, Golenser J, Loyevsky M, Tsafack A. Iron chelators: mode of action as antimalarials. Acta Haematol. 1996; 95(1): 70-7
37. Whitehead S, Peto TE. Stage-dependent effect of deferoxamine on growth of Plasmodium falciparum in vitro. Blood 1990; 76: 1250-1255.
38. Atkinson CT, Bayne MT, Gordeuk VR, Brittenham GM, Aikawa M. Stage-specific ultrastructural effects of desferrioxamine on Plasmodium falciparum. Am J Trop Med Hyg 1991; 45:593-601.
39. van Zyl RL, Havlik I, Hempelman E, MacPhail AP, McNamara L. Malaria pigment and extracellular iron: possible target for iron chelating agents. Biochem Pharmacol 1993; 45: 1431-1436.
40. Basco LK, Le Bras J. In vitro activity of chloroquine and quinine in combination with desferrioxamine against Plasmodium falciparum. Am J Haematol 1993; 42: 389-391.
41. Chevion M, Chuang L, Golenser J. Effects of zinc-desferrioxamine on Plasmodium falciparum in culture. Antimicrob Agents Chemother 1995; 39: 1902-1905.
42. Lytton SD, Mester B, Libman J, Shanzer A, Cabantchik ZI. Mode of action of iron (III) chelators as antimalarials: II. Evidence for differential effects on parasite iron-dependent nucleic acid synthesis. Blood 1994; 84: 910-915.
43. Glickstein H, Breuer B, Loyevsky M, Konijn A, Libman J, Shanzer A, Cabantchik ZI. Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells. Blood 1996; 87: 4871-4878.
44. Pattanapanyasat K, Thaithong S, Kyle DE, Udomsangpetch R, Yongvanitchit K, Hider RC, Webster HK. Flow cytometric assessment of hydroxypyridone iron chelators on in vitro growth of drug-resistant malaria. Cytometry 1997; 21: 84-91.
45. Tsafack A, Loyevsky M, Ponka P, Cabantchik ZI. Mode of action of iron (III) chelators as anti-malarials. IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives. J Lab Clin Med 1996; 127: 575-582.
46. Stahel E, Mazier D, Guillouzo A, Miltgen P, Landau I, Mellouk S, Beaudoin RL, Langlois P, Gentilini M. Iron chelators: in vitro inhibitory effect on the liver stage of rodent and human malaria. Am J Trop Med Hyg 1988; 39: 236-240.
47. Loyevsky M, Sacci JB Jr, Boehme P, Weglicki W, John C, Gordeuk VR. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol 1999; 91: 105-114.
48. Hasinoff BB, Reiders FX, Clark V. The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-l-yl) propane. Drug Metabolism and Disposition 1991; 19: 74-80.
49. Pollack S, Rossan RN, Davidson DE, Escajadillo A. Desferrioxamine suppresses Plasmodium falciparum in Aotus Monkeys. Proc Soc Experiment Biol Med 1987; 184: 162-164.
50. Yinnon AM, Theanacho EN, Grady RW, Spira DT, Hershko C. Antimalarial effect of HBED and other phenolic and catecholic iron chelators. Blood 1989; 74: 2166-2171.
51. Postma NS, Hermsen CC, Zuidema J, Eling WM. Plasmodium vinckei: optimization of desferrioxamine B delivery in the treatment of murine malaria. Exp Parasitol 1998; 89: 323-330.
52. Hershko C, Gordeuk VR, Thuma PE, Theanacho EN, Spira DT, Hider RC, Peto TE, Brittenham GM. The antimalarial effect of iron chelators in animal models and in humans with mild falciparum malaria. J Inorg Biochem 1992; 47: 267-277.
53. Golenser J, Tsafack A, Amichai Y, Libman J, Shanzer A, Cabantchik ZI. Antimalarial action of hydroxamate-based iron chelators and potentiation of desferrioxamine action by reversed siderophores. Antimicrob Agents Chemotherap 1995; 39: 61-65.
54. Gordeuk VR, Thuma PE, Brittenham GM, Zulu S, Simwanza G, Mhangu A, Flesch G, Parry D. Iron chelation with deferoxamine B in adults with asymptomatic Plasmodium falciparum parasitemia. Blood 1992a; 79: 308-312.
55. Gordeuk VR, Thuma PE, Brittenham GM, Biemba G, Zulu S, Simwanza G, Kalense P, M'hango A, Parry D, Poltera AA, Aikawa M. Iron chelation as a chemotherapeutic strategy for falciparum malaria. Am J Trop Med Hyg 1993; 48: 193-197.
56. Thuma PE, Olivieri NF, Mabeza GF, Biemba G, Parry D, Zulu S, Fassos FF, McClelland RA, Koren G, Brittenham GM, Gordeuk VR. Assessment of the effect of the oral iron chelator deferiprone on mild Plasmodium falciparum parasitemia in humans. Am J Trop Med Hyg 1998a; 58:358-364.
57. Bunnag D, Poltera AA, Viravan C, Looaresuwan S, Harinasuta T, Schundlery C. Plasmodicidal effect of desferrioxamine in human vivax or falciparum malaria from Thailand. Acta Trop 1992; 52: 59-67.
58. Traore O, Carnevale P, Kaptue-Noche L, M'Bede J, Desfontaine M, Elion J, Labie D, Nagel RL. Preliminary report on the use of desferrioxamine in the treatment of Plasmodium falciparum malaria. Am J Hematol 1991; 37: 206-208.
59. Looaresuwan S, Wilairatana P, Vannaphan S, Gordeuk VR, Taylor TE, Meshnick SR, Brittenham GM. Co-administration of desferrioxamine B with artesunate in malaria: an assessment of safety and tolerance. Ann Trop Med Parasitol 1996; 90: 551-554.
60. Gordeuk VR, Thuma PE, Brittenham GM, McLaren C, Parry D, Backenstose AR, Biemba G, Msiska R, Holmes L, McKinley E, Vargas L, Gilkeson RC, Poltera AA. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. New Engl J Med 1992b; 327: 1473-1477.
61. Thuma PE, Mabeza GF, Biemba G, Bhat GJ, McLaren C, Moyo VM, Zulu S, Khumalo H, Mabeza P, M'hango A, Parry D, Poltera AA, Brittenham GM, Gordeuk VR. Effect of iron chelation therapy on mortality in Zambian children with cerebral malaria. Trans Roy Soc Trop Med Hyg 1998b; 92: 214-218.
62. MacPherson GG, Warrell MJ, White NJ, Looareesuwan S, Warrell DA. Human cerebral malaria: a quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol 1985; 119: 385-401.
63. Oo MM, Aikawa M, Than T, Aye TM, Myint PT, Igarashi I, Schoene WC. Human cerebral malaria: a pathological study. J Neuropathol Exp Neurol 1987; 46: 223-231.
64. Aikawa M, Iseki M, Barnwell JW, Taylor D, Oo MM, Howard RJ. The pathology of human cerebral malaria. Am J Trop Med and Hyg 1990; 43 (Suppl): 30-37.
65. Sadrzadeh SM, Graf E, Panter SS, Hallaway PE, Eaton JW. Hemoglobin: a biologic Fenton reagent. J Biol Chem 1984; 259: 14354-14356.
66. Ward PA, Till GO, Kunkel R, Beauchamp C. Evidence for role of hydroxyl radical in complement and neutrophil-dependent injury. J Clin Invest 1983; 72: 369-371.
67. Ambrosio G, Zweier JL, Jacobus WE, Weisfeldt ML, Flaherty JT. Improvement of post-ischemic myocardial function and metabolism induced by administration of deferoxamine at time of reflow: role of iron in the pathogenesis of reperfusion injury. Circulation 1987; 76: 906-915.
68. Sadrzadeh SM, Anderson DK, Panter SS, Hallaway PE, Eaton JW. Hemoglobin potentiates central nervous system damage. J Clin Invest 1987; 79: 662-664.
69. Weiss G, Thuma P, Mabeza G, Werner ER, Herold M, Gordeuk VR. Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria. J Infect Dis 1997; 175:226-230.
70. Gordeuk VR, Thuma PE, McLaren CE, Biemba G, Zulu S, Poltera AA, Askin JE, Brittenham GM. Transferrin saturation and recovery from coma in cerebral malaria. Blood 1995; 85: 3297-3301.
71. van der Torn M, Thuma PE, Mabeza GF, Biemba G, Moyo VM, McLaren CE, Brittenham GM, Gordeuk VR. Loading dose of quinine in African children with cerebral malaria. Trans Roy Soc Trop Med Hyg 1998; 92:325-331.
72. Thuma PE, Weiss G, Herold M, Gordeuk V. Serum neopterin, interleukin-4 and interleukin-6 concentrations in cerebral malaria patients and the effect of iron chelation therapy. Am J Trop Med Hyg 1996; 54: 164-168.
73. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H. Immune response associated production of neopterin. J Exp Med 1984; 160: 310-316.
74. Fuchs D, Hausen A, Reibnegger G, Werner ER, Deitrich MP, Wachter H. Neopterin as a marker of activated cell-mediated immunity: Application on HIV infection. Immunol. Today 1988; 9: 150-155.
75. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Wachter H. Iron modulates interferon-gamma effects in human myelomonocytic cell line THP-1. Exp Hematol 1992; 20: 605-10.
76. Fritsche G, Larcher C, Schennach H, Weiss G. Regulatory Interactions between Iron and Nitric Oxide Metabolism for Immune Defense against Plasmodium falciparum Infection. J Infect Dis 2001; 183:1388-94.
77. Bienzle U, Fritsch KG, Hoth G, Rozdzinski E, Kohler K, Kalinowski M, Kremsner P, Rosenkaimer F, Feldmeier H. Inhibition of Plasmodium vinckei-malaria in mice by recombinant murine interferon-gamma. Acta Trop. 1988; Sep;45(3):289-90.
78. Scheibel LW, Rodriguez S. Anti-malarial activity of selected aromatic chelators. V. localization of 59Fe in Plasmodium falciparum in the presence of oxines. Prog Clin Biol Res 1989; 313: 119-149.
79. Yang Y, Ranz A, Pan HZ, Zhang ZN, Lin XB, Meshnick SR. Daphnetin: a novel anti-malarial agent with in vitro and in vivo activity. Am J Trop Med Hyg 1992; 46: 15-20.
80. Jairam KT, Havlik I, Monteagudo FSE. Possible mechanism of action of desferrioxamine and 2,2′-bipyridyl on inhibiting the in vitro growth of Plasmodium falciparum (3 strain). Biochem Pharmacol 1991; 8: 1633-1634.